Issue: June 10, 2015
May 04, 2015
1 min read
Save

Multicolor confocal scanning laser ophthalmoscopy may effectively detect retinal pathologies

Issue: June 10, 2015
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

DENVER — Multicolor confocal scanning laser ophthalmoscopy may be combined with spectral-domain OCT to detect subretinal, intraretinal and epiretinal pathology, according to a presentation here.

In a poster presented at the Association for Research in Vision and Ophthalmology annual meeting, Henry Feng, MD, and colleagues discussed a retrospective review of 159 consecutive eyes that underwent multicolor confocal scanning laser ophthalmoscopy (cSLO) with SD-OCT (Spectralis, Heidelberg) in a single session.

“Using multicolor [cSLO], we want to know which patients are most beneficial for this new technology,” Feng told Ocular Surgery News.

Multicolor reflectance showed positive percent agreement that was equal to or greater than infrared, green and blue reflectance images in detecting choroidal lesions, chorioretinal scars, peripapillary atrophy, drusen and pigment epithelial detachment. It also demonstrated the highest positive percent agreement for intraretinal and subretinal hemorrhage.

Retinal pigment epithelial atrophy was most effectively detected in infrared reflectance.

Epiretinal membrane was equally detected on green, blue, and multicolor reflectance but least detected in infrared reflectance.

Imaging artifacts were found in 23.3% of eyes, and the study authors intend to characterize further clinical findings in reference to the new technology, Feng said.

Additionally, the authors will detect defects in the nerve fiber layer in glaucoma patients, he added.

“Multicolor is a very valuable addition, especially for middle and surface pathology, in order to know which patients to use this new technology in and to quantify the ability to see different types of pathology,” Feng said. - by Kristie L. Kahl

Disclosure: Feng reports no relevant financial disclosures.